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Pain is a problem that often has to be addressed in the prehospital setting. The delivery of analgesia may
sometimes prove challenging due to problems establishing intravenous access or a harsh winter environment. To
solve the problem of intravenous access, intranasal administration of drugs is used in some settings. In cases where
vascular access was foreseen or proved hard to establish (one or two missed attempts) on the scene of the
accident we use nasally administered S-Ketamine for prehospital analgesia. Here we describe the use of nasally
administered S-Ketamine in 9 cases. The doses used were in the range of 0,45-1,25 mg/kg. 8 patients were treated
in outdoor winter-conditions in Sweden. 1 patient was treated indoor. VAS-score decreased from a median of 10
(interquartile range 8-10) to 3 (interquartile range 2-4). Nasally administered S-Ketamine offers a possible last
resource to be used in cases where establishing vascular access is difficult or impossible. Side-effects in these 9
cases were few and non serious. Nasally administered drugs offer a needleless approach that is advantageous for
the patient as well as for health personnel in especially challenging selected cases. Nasal as opposed to intravenous
analgesia may reduce the time spent on the scene of the accident and most likely reduces the need to expose the
patient to the environment in especially challenging cases of prehospital analgesia. Nasal administration of S-
ketamine is off label and as such we only use it as a last resource and propose that the effect and safety of the
treatment should be further studied.
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The county of Jämtland and Härjedalen is a sparsely popu-
lated area in the central/west part of Sweden close to the
mountain-range that borders to Norway. Its area is 49000
km2 which is slightly greater than that of Denmark. The
only town, Östersund, harbours the only hospital in the
county and is situated 100–180 kilometers from the most
popular mountain areas with heavy downhill and cross-
country skiing activities and many ski resorts. Due to the
long distances involved in prehospital care, the road am-
bulance service is complemented by an air ambulance, a
Dauphine AS 365 N2. It is operated by a standard crew of
three; a pilot, a navigator/technician/paramedic and an
anesthesia nurse. The latter always has many years experi-
ence of prehospital and in-hospital anesthetic care. An* Correspondence: joakim.johansson@jll.se
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distribution, and reproduction in any mediumanesthesiologist from the hospital is included as occasion
requires. The largest ski resort, Åre, also features a ski pa-
trolling anaesthesia nurse (MN) designated to provide
prehospital care.
The standard prehospital analgesia is intravenous fen-
tanyl or morphine but establishing intravenous access may
be challenging in some cases. In all cases it is desirable to
limit the rescue-time, even more so when temperatures
are low and hypothermia is a risk. The nasal mucosa is
richly vascularised and uptake to the blood of aerosolized
drugs with certain characteristics is possible [1].
We have found one report indicating use of nasal keta-
mine in mountain rescue [2] and one previous case
report [3].
This case-series describes experiences of using nasal
S-ketamine for prehospital analgesia in nine especially
challenging cases during 2 winter seasons 2010–1012.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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This is a series of nine cases that were treated on the scene
where the decision to use off-label nasal S-ketamine were
taken by the responsible nurse/physician. Hence, we
present a case-series and as such no informed consent for
treatment was sought from the patients. The regional eth-
ics review board was approached with an application but
waived the need for an approval to publish the data. The
reason was that since the goal of our treatment was to de-
liver analgesia and not to test the effect of the medicine, it
was considered a case-series which is not dealt with by the
ethics review board. The board gave a guiding statement
though, regarding the publication of data, that with in-
formed consent this would be ethical.
Informed consent for publication of data was achieved
later from patients or in cases of minors from one of
their parents.
The presented nasal administration of S-ketamine was
considered only in cases of traumatic injuries when vascu-
lar access was foreseen or proven problematic (1 or 2
missed attempts). Patients with a suspected traumatic
brain injury or facial trauma with nasal bleed were not
considered. A total of 14 cases were treated during the
two winter seasons 2010–2012, nine cases were evaluated
in the case-series. The reasons for not being presented are
other strong analgetics given in parallel (sublingual fen-
tanyl or intravenous morphine after iv-access was
achieved) or that patients could not be reached for an in-
formed consent.
We consider this treatment a last resort and use it in a
minority of patients. During two normal years our
prehospital service handles approximately 700 traumatic
cases that are brought in to Östersund hospital. The 14
treated cases hence constitute approximately 2% of trauma
cases.
Preservative-free S-ketamine 25 mg/ml (Ketanest®,
Pfizer, New York, NY, USA) was delivered by means of a
so called MAD 300 (Mucosal Atomization Devise, LMA
North America Inc., San Diego, Ca, USA) and a disposable
plastic 5 ml-syringe with a luer-lock connection (BD,
Franklin Lakes, NJ, USA). The first dose given was 0,5
mg/kg body weight and thereafter additional doses were
given as needed. The total dose was limited to 1,0 mg/kg
body weight in adults and 1,5 mg/kg body weight in chil-
dren. We delivered no more than 0,5 ml per nostril at a
time and waited at least 2 minutes before the next admin-
istration in the same nostril.
The patients were asked to score their pain on a scale
from 1 (min) to 10 (max) before and five to ten minutes
after the treatment. The treating nurse/physician paid
attention to side-effects (hypersecretion, signs of vertigo
or nausea).
Pain-score was considered an ordinal variable and test-
ing for differences before and after analgesia was donewith Wilcoxons matched pairs test. A p-value <0.05 was
considered statistically significant. Statistica 10 (StatSoft®
Inc, Tulsa, OK, USA) was used for analysis.
Results
The characteristics of the patients, dose (mg/kg body
weight), pain scoring and registered side-effects are
presented in Table 1.
Median pain-score before treatment at the scene of
the accident was 10 (interquartile range 8–10) and me-
dian pain-score after was 3 (interquartile range 2–4)
(Figure 1). The difference was significant (p=0.018).
Discussion
When discussing pain treatment, the placebo effect must
be considered. It is most likely reinforced by several fac-
tors in prehospital care, such as the ability of health
personnel to act confident and reassuring, whether a
relative or friend can accompany on the ride to the hos-
pital, and so on. Other factors, beside pharmacological,
that affect prehospital pain are the effectiveness of
immobilization of the fractured limb [4] and the ability
of health providers to move patients smoothly. In our
case-series, the substantial drop in pain-score after
S-ketamine administration strongly suggests an effect of
the treatment. The contribution of placebo and other ef-
fects can’t be estimated in this case-series.
The median pain-score decreased from 10 to 3 (mean
from 8,44 to 3,0). We believe that a pain-score of 3 is a
reasonable target on the scene of an accident. Two pa-
tients were children (below 12 years old) and a total of
five patients were 14 years old or younger. The nurses
pointed out that nasal analgesia felt the most purposeful
in young patients because of difficulties with vascular ac-
cess and the non-cooperative state of some young pa-
tients in distress.
The need for a vascular access is not only related to
analgesia but also to the risk of occult bleeding and
hence to the possible need for resuscitation during
transport or to give additional drugs that are not suited
for nasal administration.
Patient # 4 scored 6–6 but received a dose similar to the
other patients. It is unclear why the effect was insufficient.
Large differences in plasma concentration after nasal keta-
mine administration have by earlier investigators been at-
tributed to several factors: a variable amount of the drug
swallowed [5] which may in turn depend on the technique
used for administration; local nasal cavity factors such as
swelled nasal mucosa with diminished air exchange in the
nostril; local factors at the nasal mucosa such as increased
amount of mucus.
Patient # 6 scored 3–3 and hence was not in great dis-
tress before treatment. In some cases the anesthesia
nurse tries to foresee a possible need for analgesia in
Table 1 Demographics, doses, pain-scores at the scene of accident, and type of injury
Case # Age Sex Weight Dose mg/kg Pain score before Pain score after Injury
1 7 M 28 0,45 10 3 Fractured lower leg
2 19 F 60 0,83 10 4 Fractured clavicle
3 13 M 40 1,25 10 6 Fractured ulna
4 22 M 90 1,11 6 6 Fractured lower leg
5 14 M 52 0,96 7,5 1 Contusion leg
6 36 M 76 0,98 3 3 Fractured lower leg
7 7 M 35 1,1 9 2 Fractured femur
8 13 M 45 0,83 10 2 Fractured humerus
9 17 F nd nd 10 1 Knee distorsion
Median 16 48,5 0,94 10(8–10) 3 (2–4)
Data for Pain-score are presented as median (25th–75th percentile).
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fracture and hence administers analgesics to a patient in
no apparent present distress. This may have been the
case with patient # 6.
S-ketamine exerts its actions in the brain and if the effect
from nasal administration is via a direct olfactory mucosal
uptake to the brain or from the systemic effect from an up-
take in the blood and then via the bloodstream to the brain
is not clear. It is clear though from a study by Weber et al.
that clinically relevant concentrations in the blood are ac-
complished within minutes of a nasal administration [6].
The onset of analgesia (3–10 minutes in our experience)
suggests that the effect comes via the blood stream.
In accordance with the results of Malinovsky et al. [5],
some patients had a rather slow analgesic onset. This may
depend on a variable amount of the drug deposited on the














Figure 1 Pain-score before and 5–10 minutes after analgesia with nas
statistically significant difference in pain score (p=0.018).turn may depend on local conditions at the nasal mucosa
or mishaps at administration (sneezing or coughing). We
also believe that the direction that one sprays the drug is
important. If the spray hits a solid object early on, for ex-
ample the nasal partition wall, it will all condense to a li-
quid form and run either down to pharynx or out of the
nostril, depending on the position of the head. It is more
likely to have a successful administration if the patient co-
operates and inhales through the nostril in question and
not to administer more than 0,5-1,0 ml at a time (depend-
ing on patient size).
S-ketamine was developed to decrease psychotomimetic
side-effects of racemic ketamine but a review suggests that
this is not clearly the case [7]. Another side-effect of keta-
mine as well as S-ketamine is hypersecretion. Neither of
these complications was reported in our patients, nor nau-
sea although three of them experienced vertigo. Manyr delivery of nasal S-ketamine
 Median 
 25%-75% after
al S-ketamine. Data presented as median (quartiles). There was a
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ommend warning on beforehand, especially when treating
children. S-ketamine potency is twice that of racemic keta-
mine, hence equal volumes of the drug would in theory
have the same biological effect since S-ketamine is access-
ible in 25 mg/ml and ketamine in 50 mg/ml.
S-ketamine is, as opposed to ketamine, free of the pre-
servatives that have been linked to neural toxicity [8,9].
This is why S-ketamine is used for epidural anaesthesia
and ketamine not. Since there may be a direct uptake
from the nasal mucosa via the olfactory lobe to the cen-
tral nervous system, there have been recommendations
not to use ketamine for nasal administration either. The
issues of the potential neurotoxicity is still under debate
and while Vranken et al. found a neurotoxic effect of
daily intratecal administration for one week of preserva-
tive free S-ketamine in rabbits, Rojas et al. showed that a
single epidural injection of 1 mg/kg S-ketamine did not
produce neural lesions in dogs [10].
We found that patients always responded to verbal stim-
uli but some were not adequate in their response. We had
no impression of compromised airway or airway reflexes.
To summarize, the opinion of our experienced pre-
hospital staff was that nasal S-ketamine offered a fast,
easy, and essentially non-invasive way of reducing
acute pain secondary to trauma, without appreciable
side effects.
Further advantages are a relatively low cost of the
treatment, a needleless approach that diminish the risk
of transmission of blood-borne infections, and sup-
posedly a reduced rescue-time which is particularly valu-
able in a cold or otherwise dangerous environment. All
together these benefits make it an appealing strategy for
prehospital service in general and even more so in devel-
oping countries. The main reason why we only use it as
a last resource strategy is that it is off label use of the
drug. If our impression of a safe and relatively rapid an-
algesic effect of nasal S-ketamine could be confirmed, it
opens for a widening of its formal indications which
would facilitate improved prehospital pain therapy.
The limitation of our data is first of all that it is not a
study but only a series of nine case-reports and as such
not suitable for any generalisation. There is no control-
group and there is a possible bias in that the decision to
use the nasal strategy was done on the scene.
We suggest that the feasibility of nasal S-ketamine for
prehospital analgesia should be evaluated in a formal
randomised controlled trial. Such a trial would be hard
to design as blinded but may as well have an open de-
sign. It might look into questions such as the safety of
the treatment, the effect of nasal analgesia compared to
standard care, onset time, the frequency and type of
side-effects and the necessary rescue-time spent on the
scene of accident.Conclusion
We conclude that nasal administration of S-ketamine
for treatment of traumatic pain on the scene of an acci-
dent seems to be a promising alternative in cases where
vascular access is foreseen or proven problematic.
Competing interests
The authors declare that they have no conflicts of interests.
Authors’ contributions
JJ, JS, ES and HZ conceived the idea to test nasal S-ketamine for challenging
cases and decided to do a follow up on the efficacy of treatment. JJ wrote
the manuscript. JS helped designing the prehospital pain therapy protocol
for challenging cases. MN included patients and has helped preparing the
manuscript as well as refining the pain therapy protocol. FS helped with
preparation of the manuscript and interpretation of data. HZ revised the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
We wish to thank the personnel at the air-ambulance in Östersund, nurse
Ulrika Wärvik as well as residents in anaestesiology Maria Schollin-Borg and
Sven Grauman for documenting their cases.
This work was supported by the research and development unit, Jämtland
County Council, Sweden.
Author details
1The research and development unit, Jämtland county council, Östersund,
Sweden. 2Department of Anaesthesiology and Intensive Care, Östersund
hospital, Östersund SE 83183, Sweden. 3Department of Anaesthesia and
Intensive Care, Linköping University Hospital, Linköping, Sweden.
4Department of Clinical and Experimental Medicine, Faculty of Health
Sciences, Linköping University, Linköping, Sweden. 5Department of
Anaesthesiology and Intensive Care, Uppsala University, Uppsala, Sweden.
Received: 30 March 2012 Accepted: 5 May 2013
Published: 14 May 2013
References
1. Dale O, Hjortkjaer R, Kharasch ED: Nasal administration of opioids for pain
management in adults. Acta Anaesthesiol Scand 2002, 46:759–770.
2. Ellerton J, Paal P, Brugger H: Prehospital use of ketamine in mountain
rescue. Emerg Med J 2009, 26:760–761.
3. Reid C, Hatton R, Middleton P: Case report: prehospital use of intranasal
ketamine for paediatric burn injury. Emerg Med J 2011, 28:328–329.
4. Ellerton J, et al: Immobilization and splinting in mountain rescue. Official
Recommendations of the International Commission for Mountain
Emergency Medicine, ICAR MEDCOM, Intended for Mountain Rescue
First Responders, Physicians, and Rescue Organizations. High Alt Med Biol
2009, 10:337–342.
5. Malinovsky JM, et al: Ketamine and norketamine plasma concentrations after
i.v., nasal and rectal administration in children. Br J Anaesth 1996, 77:203–207.
6. Weber F, et al: S-ketamine and s-norketamine plasma concentrations
after nasal and i.v. administration in anesthetized children.
Paediatr Anaesth 2004, 14:983–988.
7. Engelhardt W: [Recovery and psychomimetic reactions following
S-(+)-ketamine]. Anaesthesist 1997, 46(Suppl 1):S38–42.
8. Errando CL, et al: Subarachnoid ketamine in swine–pathological findings after
repeated doses: acute toxicity study. Reg Anesth Pain Med 1999, 24:146–152.
9. Malinovsky JM, et al: Is ketamine or its preservative responsible for
neurotoxicity in the rabbit? Anesthesiology 1993, 78:109–115.
10. Rojas AC, et al: The effects of subarachnoid administration of
preservative-free S(+)-ketamine on spinal cord and meninges in dogs.
Anesth Analg 2011, 114(2):450–455.
doi:10.1186/1757-7241-21-38
Cite this article as: Johansson et al.: Prehospital analgesia using nasal
administration of S-ketamine – a case series. Scandinavian Journal of
Trauma, Resuscitation and Emergency Medicine 2013 21:38.
